Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a nebulizer beat an inhaler for COPD symptom relief?

NCT ID NCT07133880

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial asks whether giving COPD medication through a nebulizer works better than a dry powder inhaler. It enrolls adults over 40 with COPD symptoms and significant air trapping. Participants receive either a nebulizer or inhaler treatment, and researchers compare changes in lung volume and symptom scores. The goal is to see if one delivery method improves breathing and quality of life more than the other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Long-acting bronchodilators (LAMA/LABA combination) delivered via nebulizer or dry powder inhaler
What this could lead to
If nebulizers prove better, it could guide COPD treatment choices, improving symptom relief and lung function for patients who struggle with inhalers.
What could go wrong
This is a phase 4 trial with 72 participants, so results may not apply to all COPD patients. Individual responses vary, and the study may not show a clear difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 40 years 2. Either sex 3. Current smoker or past cigarette smoking history of \> 10 pack-years 4. Symptoms of COPD (cough, sputum production, shortness of breath) 5. Modified Medical Research Council Dyspnea Scale (mMRC) score ≥2 or CAT score ≥10 at Screening/Run-in visit 6. A PIFR \> 30 at screening 7. FEV1/FVC ratio \< 70% (within the past 12 months) 8. Residual volume (RV) ≥ 120% predicted (within the past 12 months Exclusion Criteria: 1. Diagnosis of asthma (Verification via medical record and/or patient report) 2. Previously diagnosed atrial fibrillation with rapid ventricular response (heart rate \> 110 bpm) or ventricular arrhythmia (ventricular tachycardia) (Verification via medical record and/or patient report) 3. Acute myocardial infarction within 12 weeks of patient study registration (Verification via medical record and/or patient report) 4. Acute exacerbation of congestive heart failure (Verification via medical record and/or patient report) 5. Acute exacerbation of COPD within 8 weeks (Verification via medical record and/or patient report) 6. Recent (within 8 weeks) h/o eye surgery (Verification via medical record and/or patient report) 7. Uncontrolled glaucoma (Verification via medical record and/or patient report) 8. Known diagnosis of liver cirrhosis (Verification via medical record and/or patient report) 9. Known diagnosis of chronic renal insufficiency (defined as a previous serum creatinine \> 2.5 mg/dL - Verification via medical record and/or patient report) 10. Intolerance to any of the study drugs 11. Patients receiving long-term azithromycin 12. Planned surgery requiring hospital admission within 3 months 13. Currently enrolled in a pulmonary rehabilitation program 14. Inability to give informed consent 15. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants) 16. Inability to understand instructions or comply with the study protocol 17. Participation in another investigational drug clinical trial within 30 days of patient study registration Medical history can be confirmed by medical records and/or verbal confirmation from patients. However, Inclusion criteria 6 \& 7 must be verified by a previous PFT report dated within 6 months of screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Tennessee Graduate School of Medicine

    RECRUITING

    Knoxville, Tennessee, 37920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.